|
Age, years
|
54 ± 16
|
55 ± 10
|
0.62
|
|
Female, n (%)
|
162 (66)
|
263 (81)
|
<0.001
|
|
BMI, kg/m2
|
30 ± 3
|
28 ± 5
|
<0.001
|
|
Abdominal circumference, cm
|
100 ± 6
|
97 ± 13
|
<0.001
|
|
Cardiovascular data
| | | |
|
CV risk factors, n (%)
|
|
Current smoker
|
47 (19)
|
64 (20)
|
0.83
|
|
Obesity
|
67 (27)
|
104 (32)
|
0.20
|
|
Hypertension
|
92 (37)
|
101 (31)
|
0.13
|
|
Diabetes mellitus
|
42 (17)
|
42 (13)
|
0.16
|
|
Blood pressure, mm Hg
|
|
Systolic
|
139 ± 8
|
133 ± 19
|
<0.001
|
|
Diastolic
|
84 ± 5
|
81 ± 12
|
0.001
|
|
Statins, n (%)
|
66 (27)
|
104 (32)
|
0.19
|
|
Disease-related data
|
|
CRP at time of study, mg/l
|
2.0 (1.1–4.6)
|
2.6 (1.3–6.1)
|
0.023
|
|
Disease duration, years
| |
8 (4–15)
| |
|
ESR at time of study, mm/1° hour
| |
25 (12–45)
| |
|
Rheumatoid factor, n (%)
| |
218 (67)
| |
|
ACPA, n (%)
| |
179 (55)
| |
|
DAS28-ESR
| |
2.32 ± 1.19
| |
|
DAS28-PCR
| |
2.54 ± 1.05
| |
|
SDAI
| |
12 (6–20)
| |
|
CDAI
| |
8 (4–14)
| |
|
HAQ
| |
0.750 (0.250–1.250)
| |
|
Current drugs, n (%)
|
|
Prednisone
| |
123 (38)
| |
|
Prednisone doses, mg/day
| |
5 (3–5)
| |
|
NSAIDs
| |
154 (48)
| |
|
DMARDs
| |
277 (86)
| |
|
Methotrexate
| |
238 (74)
| |
|
Leflunomide
| |
72 (22)
| |
|
Hydroxychloroquine
| |
37 (11)
| |
|
Sulfasalazine
| |
25 (8)
| |
|
Anti-TNF therapy
| |
68 (21)
| |
|
Tocilizumab
| |
17 (5)
| |
|
Rituximab
| |
6 (2)
| |
|
Abatacept
| |
6 (2)
| |
|
JAK inhibitors
| |
7 (2)
| |
|
Historical disease-related data
| | | |
|
History of extraarticular manifestations, n (%)
| |
24 (7)
| |
|
Erosions, n (%)
| |
113 (35)
| |
|
CRP at time of disease diagnosis, mg/l
| |
6.4 (2.5–17.1)
| |
|
CRP >3 at time of disease diagnosis, n (%)
| |
152 (47)
| |
|
ESR at disease diagnosis, mm/1° hour
| |
31 ± 19
| |
|
Subclinical atherosclerosis
| | | |
|
Carotid IMT, microns
| |
698 ± 137
| |
|
Carotid plaques, n (%)
| |
124 (38)
| |
